R&D Team

Formulation Scientist - Fred Mu, MSc.

Mr. Mu has over 20 years of working experience as QC, QA, Manufacturing and R&D in the pharmaceutical and Nutraceutical industry in Canada, Japan and China. Mr. Mu worked as the QC/QA Manager for an international pharmaceuticals company and as QA and Manufacture Supervisor for Organika Health Products Inc. and Capwork Nutrition Ltd. From 1989 to 2006, Mr. Mu was the QC/QA/R&D Manager in Qingdao Huazhong Pharmaceuticals Ltd., an affiliated company of Kanebo Pharmaceuticals Inc. of Japan. Mr. Mu received his Master of Science from College of Pharmacy, Fudan University, China.

Chemistry Scientist - Joshua Yu, Ph.D,
Dr. Joshua Yu received his doctoral degree from the University of Göttingen, Germany. He continued his post-doctoral research in the University of British Columbia (UBC), Canada. Dr. Yu has over 20 years of research experience in extraction and purification of active phytomedicinal compounds from herbs, modification of structure of the active molecules from herbs, and synthesis of small molecule compounds, Bioinorganic Chemistry, Organometallics and Nano-Cluster material Chemistry. Dr. Yu has published over 20 academic papers on various world renowned journals and magazines and had applied several technology patents.

Clinical Director - Sherman Zhao, MD, Ph.D
Dr. Sherman Zhao graduated from the Shanghai Medical University with a bachelor's degree in laboratory medicine. At the Peking University, he received his doctoral degree in Pharmacology.  When Dr. Zhao was later studying in the Georgia State University, United States, he completed his post-doctoral research. Dr. Zhao has gained profound knowledge and clinical experience in treating cancer and Alzheimer’s disease and has published over 10 papers. He has also been engaged in the research and development of novel drugs in domestic and foreign pharmaceutical companies. Dr. Zhao was the key person involved in the development of two phytopharmaceuticals which were approved for clinical trial in 2005, and is the principal investigator of the undergoing Phase III clinical trial.